Crescent Grove Advisors LLC Trims Position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Crescent Grove Advisors LLC decreased its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 19.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,907 shares of the financial services provider’s stock after selling 14,267 shares during the quarter. iShares Nasdaq Biotechnology ETF accounts for about 1.2% of Crescent Grove Advisors LLC’s portfolio, making the stock its 19th largest position. Crescent Grove Advisors LLC owned approximately 0.08% of iShares Nasdaq Biotechnology ETF worth $5,777,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Albion Financial Group UT increased its holdings in shares of iShares Nasdaq Biotechnology ETF by 1.3% in the fourth quarter. Albion Financial Group UT now owns 101,575 shares of the financial services provider’s stock worth $9,795,000 after acquiring an additional 1,273 shares in the last quarter. Smith Moore & CO. grew its stake in iShares Nasdaq Biotechnology ETF by 29.3% in the third quarter. Smith Moore & CO. now owns 5,724 shares of the financial services provider’s stock valued at $698,000 after purchasing an additional 1,296 shares in the last quarter. Simplex Trading LLC bought a new position in iShares Nasdaq Biotechnology ETF in the fourth quarter valued at approximately $792,000. Virtu Financial LLC bought a new position in iShares Nasdaq Biotechnology ETF in the fourth quarter valued at approximately $1,191,000. Finally, Lido Advisors LLC grew its stake in iShares Nasdaq Biotechnology ETF by 25.9% in the third quarter. Lido Advisors LLC now owns 4,256 shares of the financial services provider’s stock valued at $519,000 after purchasing an additional 875 shares in the last quarter. 66.51% of the stock is currently owned by hedge funds and other institutional investors.

IBB opened at $109.75 on Thursday. iShares Nasdaq Biotechnology ETF has a 12-month low of $89.01 and a 12-month high of $122.97.

COPYRIGHT VIOLATION WARNING: This article was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/02/14/crescent-grove-advisors-llc-lowers-position-in-ishares-nasdaq-biotechnology-etf-ibb.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Story: How to trade on quiet period expirations

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply